Shares of Adamis Pharmaceuticals Corp. (NASDAQ:ADMP) reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $2.55 and last traded at $2.63, with a volume of 189,346 shares traded. The stock had previously closed at $2.65.

Separately, Maxim Group reduced their target price on Adamis Pharmaceuticals Corp. from $17.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday, July 21st.

The company’s market cap is $40.17 million. The stock has a 50 day moving average of $2.89 and a 200-day moving average of $5.34.

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.